Segment Information (Details) (USD $) In Thousands, unless otherwise specified	1 Months Ended	3 Months Ended								12 Months Ended
	Jun. 30, 2011 item	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013 item	Dec. 31, 2012	Dec. 31, 2011
Segment Information
Number of operating segments	2									1
Number of commercial products										3
Revenues, cost of revenues and gross profit
Revenues										$ 1,106,944	$ 906,123	$ 741,094
Cost of revenues										131,127	119,297	88,904
Gross profit		247,519	269,290	245,175	213,833	202,766	212,949	192,199	178,912	975,817	786,826	652,190
Remodulin
Revenues, cost of revenues and gross profit
Revenues										491,179	457,969	430,132
Cost of revenues										59,314	57,618	52,329
Gross profit										431,865	400,351	377,803
Tyvaso
Revenues, cost of revenues and gross profit
Revenues										438,793	325,614	240,382
Cost of revenues										60,831	53,825	31,934
Gross profit										377,962	271,789	208,448
Adcirca
Revenues, cost of revenues and gross profit
Revenues										176,972	122,540	70,580
Cost of revenues										10,982	7,854	4,641
Gross profit										$ 165,990	$ 114,686	$ 65,939